Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company NKT Therapeutics Inc.
DescriptionHumanized mAb targeting invariant NK T (iNKT) cells
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSickle cell disease
Indication DetailsTreat sickle cell disease
Regulatory Designation U.S. - Fast Track (Treat sickle cell disease);
U.S. - Orphan Drug (Treat sickle cell disease)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today